title: Loss of CD151/Tspan24 from the complex with integrin α3β1 in invasive front of the tumour is a negative predictor of disease-free survival in oral squamous cell carcinoma.
abstract: OBJECTIVE
  The study aimed to assess the role of CD151-integrin α3β1 (INGA3) complex as a potential prognostic indicator in OSCC and to examine whether mapping of its expression in the invasive front separately from that in the rest of the tumour would have an impact on the predictive value of the results. CD151/INGA3 profiles were compared with that of EGFR.
  
  
  METHODS
  Protein distributions were analysed either in the whole tumour (W) or separately, (i) the main tumour mass (TU) and (ii) the invasive front (IF) in 83 OSCC samples using immunohistochemistry.
  
  
  CONCLUSIONS
  There was no statistical association between any of the proteins scored in W and clinicopathologic features or patient survival. When examined separately, significant associations were shown for (i) CD151 and EGFR in TU (p=0.036) and (ii) tumour grade and EGFR in both TU (p=0.045) and IF (p=0.030). INGA3 was present predominantly in the tumour-host interface, significantly stronger in IF than TU (p=0.021). An association with 5-year disease-free survival was close to significant for INGA3 (TU and IF) (p=0.050) but not the CD151/INGA3 complex. Expression of CD151/INGA3 at the IF might reflect tumour behaviour pertinent to patient outcome.
authors.affiliation: Department of Cellular Pathology, University of Birmingham, Birmingham B15 2TT, UK. hanna.romanska@gmail.com
authors.forename: H M
authors.initials: HM
authors.lastname: Romanska
authors.forename: P
authors.initials: P
authors.lastname: Potemski
authors.forename: S I
authors.initials: SI
authors.lastname: Collins
authors.forename: H
authors.initials: H
authors.lastname: Williams
authors.forename: S
authors.initials: S
authors.lastname: Parmar
authors.forename: F
authors.initials: F
authors.lastname: Berditchevski
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D015331:Cohort Studies; D018572:Disease-Free Survival; D004848:Epithelium / Q000473:pathology; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D039422:Integrin alpha3 / Q000032:analysis; D039201:Integrin alpha3beta1 / Q000032:analysis*; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000473:pathology; D009062:Mouth Neoplasms / Q000473:pathology*; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D060185:Tetraspanin 24 / Q000032:analysis*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C554715:CD151 protein, human; D039422:Integrin alpha3; D039201:Integrin alpha3beta1; D060185:Tetraspanin 24; C512478:EGFR protein, human; D066246:ErbB Receptors